# Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)

> **NCT04846868** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 620 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Iclepertin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04846868
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-08
- **Primary completion:** 2024-09-17
- **Final completion:** 2024-10-01
- **Target enrollment:** 620 (ACTUAL)
- **Last updated:** 2025-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04846868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04846868, "Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04846868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*